Cytokinetics(US:CYTK) Prnewswire·2025-10-23 17:37Core Points - Faruqi & Faruqi, LLP is investigating potential claims against Cytokinetics, Incorporated, with a deadline for investors to seek lead plaintiff status in a federal securities class action by November 17, 2025 [1][3][6] - The complaint alleges that Cytokinetics made materially false and misleading statements regarding the New Drug Application (NDA) submission and approval process for aficamten, specifically about the expected FDA approval timeline [3][4] - The company failed to disclose significant risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS) from its NDA submission, which could delay the regulatory process [3][4] - Following the revelation of these issues during an earnings call on May 6, 2025, investors suffered significant losses as the stock price was artificially inflated prior to the disclosure [4][5] Company Information - Cytokinetics, Incorporated is facing legal scrutiny due to allegations of misleading investors regarding its drug approval process [1][3] - The firm Faruqi & Faruqi has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [2] Legal Proceedings - The lead plaintiff in the class action will be the investor with the largest financial interest who is also typical of the class members [6] - Any member of the putative class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [6]